综合性成本效益分析,以评估型肝炎的治疗价值
Jacquelyn W Chou1, Marlon Graf, Oliver Díaz Espinosa
1PRECISIONheor, 2 Bethesda Metro Center, Ste 850, Bethesda, MD 20814.
The American journal of managed care
|January 3, 2024
概括
直接作用抗病毒药物 (DAA) 在治疗C型肝炎病毒 (HCV) 方面具有成本效益. 综合性成本效益分析 (GCEA) 显示,DAA与较旧的治疗方法相比,价值提高了10倍以上.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 公共卫生 公共卫生
背景情况:
- 型肝炎病毒 (HCV) 构成了严重的公共卫生负担.
- 直接作用抗病毒药物 (DAA) 为HCV提供了一个新的治疗模式.
- 传统的成本效益分析 (CEA) 可能无法完全捕捉DAA的价值.
研究的目的:
- 为了估计DAA在HCV治疗中的综合价值,与干扰素α和利巴维林 (PEG/riba) 相比.
- 采用通用的成本效益分析 (GCEA) 来评估社会层面的价值.
- 扩展马尔科夫模拟模型,包括市场动态和更广泛的价值元素.
主要方法:
- 通过循序渐进的过程,将新的价值元素添加到传统的CEA模型中.
- 对DAA与PEG/riba.的增量成本效益比率 (ICER) 进行了估计.
- 扩展了HCV的离散时间马尔科夫模拟模型,以纳入市场动态和更广泛的价值.
主要成果:
- 传统的HTA风格的CEA产生了每次质量调整寿命年 (QALY) 的ICER为64,512美元.
- 结合传输动态,动态定价和有效性,将ICER降低到每QALY的6406美元.
- 完全实现的GCEA,包括泛化和生产力损失,进一步将ICER降低到每QALY4487美元 (减少93%).
结论:
- 即使使用传统方法,DAA也是对HCV的成本有效的治疗方法.
- 整合更广泛的价值元素显著提高了DAA的成本效益.
- 在HCV治疗中,GCEA对于全面的决策至关重要.
更多相关视频
23:56Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
16.7K
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.2K
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
108
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
108
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
Hazard Ratio
129
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
129
Time Course of Drug Effect
2.1K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129
